List of Keppra Xr drug patents

Keppra Xr is owned by Ucb Inc.

Keppra Xr contains Levetiracetam.

Keppra Xr has a total of 1 drug patent out of which 0 drug patents have expired.

Keppra Xr was authorised for market use on 12 September, 2008.

Keppra Xr is available in tablet, extended release;oral dosage forms.

The generics of Keppra Xr are possible to be released after 17 September, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858122 UCB INC Extended release formulation of levetiracetam
Sep, 2028

(5 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 12 September, 2008

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of KEPPRA XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic